Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Keramidas
Michelle R. Keramidas, Garland, TX US
| Patent application number | Description | Published |
|---|---|---|
| 20090023263 | METHOD TO MANUFACTURE A THIN FILM RESISTOR - A method for manufacturing a semiconductor device that method comprises forming a thin film resistor by a process that includes depositing a resistive material layer on a semiconductor substrate. The process also includes depositing an insulating layer on the resistive material layer, and performing a first dry etch process on the insulating layer to form an insulative body. The process further includes performing a second dry etch process on the resistive material layer to form a resistive body. The resistive body and the insulative body have substantially identical perimeters. | 01-22-2009 |
Panagiotis Keramidas, Carindale AU
| Patent application number | Description | Published |
|---|---|---|
| 20100035955 | Stabilised Composition Comprising ACE Inhibitors - A pharmaceutical composition comprising a) an ACE inhibitor prone to degradation or a pharmaceutically acceptable acid addition salt thereof; b) a stabilizing amount of an alkaline stabilizing agent; and c) pharmaceutically acceptable excipients wherein the composition further includes moisture controlling means. | 02-11-2010 |
| 20100092549 | Dosage Form Containing Two or More Active Pharmaceutical Ingredients in Different Physical Forms - A dosage form for administration of two or more active pharmaceutical ingredients to a subject, comprising a first pharmaceutical composition comprising a first active pharmaceutical ingredient and optionally one or more pharmaceutically acceptable excipients in a first physical form selected from the group consisting of powder, granule, pellet, bead or mini-tablet form, and at least a second pharmaceutical composition comprising a second active pharmaceutical ingredient and optionally one or more pharmaceutically acceptable excipients in a second physical form selected from the group consisting of granule, pellet, bead, mini-tablet or tablet form, wherein the composition is characterised in that said first and second physical forms are selected to be different to minimise interactions between said first and second pharmaceutical compositions and to allow separation of said first and second pharmaceutical compositions for analysis on the basis of size difference. | 04-15-2010 |
| 20100104636 | Pharmaceutical Compound and Composition - A pharmaceutical composition comprising rosiglitazone or a pharmaceutically acceptable salt thereof wherein said rosiglitazone has a median particle size diameter of about 5 microns to about 20 microns. | 04-29-2010 |
| 20100330172 | CONTROLLED-RELEASE PHARMACEUTICAL FORMULATION - A pharmaceutical formulation comprising desvenlafaxine having an MMD of between about 5 μm and about 100 μm, or a pharmaceutically acceptable salt thereof, and at least one matrix rate-controlling pharmaceutically acceptable polymer, solid unit dosage form containing it, methods for preparing such a formulation and for its use to treat depression and related disorders and diseases. | 12-30-2010 |
| 20110070299 | DELAYED RELEASE PHARMACEUTICAL COMPOSITION OF DULOXETINE - A pharmaceutical composition comprising duloxetine or a pharmaceutically acceptable salt thereof and one or more pharmaceutically acceptable excipient(s) characterised in that the duloxetine has a D | 03-24-2011 |
Panagiotis Keramidas, Queensland AU
| Patent application number | Description | Published |
|---|---|---|
| 20090169617 | Controlled Release Formulations Comprising Uncoated Discrete Unit(s) and an Extended Release Matrix - A controlled-release formulation comprising one or more distinct and discrete units located in physical juxtaposition to enable administration to a patient in need of treatment in a single dose, characterised in that the or each unit comprise(s): (i) a unit dose of an active pharmaceutical ingredient or pharmaceutically acceptable salt thereof; (ii) one or more extended-release agent(s); and, optionally, (iii) one or more pharmaceutically acceptable excipients, wherein the sum of the unit dose(s) constitutes a pharmaceutically effective amount of the active pharmaceutical ingredient. | 07-02-2009 |
| 20110184039 | PHARMACEUTICAL FORMULATION - A pharmaceutical composition comprising: a) a 5-HT1 agonist; b) an NSAID; and c) a disintegrant characterised in that the disintegrant comprises between about 15 to about 50% w/w based on the weight of the composition, said composition optionally comprising one or more other pharmaceutically acceptable excipients. | 07-28-2011 |
Panagiotis Peter Keramidas, Queensland AU
| Patent application number | Description | Published |
|---|---|---|
| 20090220609 | PROCESS TO CONTROL PARTICLE SIZE - A multi-stage process to control the particle size of a pharmaceutical substance comprising the steps of: passing the pharmaceutical substance through a first stage of a particle size reduction process with a first set of particle size control parameters to obtain a feedstock of reduced median particle size and lesser distribution of median particle size for a second stage of a particle size reduction process; passing the feedstock, through a second stage of a particle size reduction process with a second set of particle size control parameters; optionally, using the product of the second stage or subsequent stages as a feedstock in further stages of a multi-stage particle size reduction process with a set of particle size control parameters for each stage; and collecting a pharmaceutical substance with a median particle size greater than 10 μm and with a narrow, reproducible distribution of median particle sizes. | 09-03-2009 |
Panaglotis Keramidas, Queensland AU
| Patent application number | Description | Published |
|---|---|---|
| 20110206770 | ATOVAQUONE WITH A PARTICLE SIZE DIAMETER RANGE (D90) OF GREATER THAN 3 MICRONS TO ABOUT 10 MICRONS - Atovaquone or a pharmaceutically acceptable salt thereof having a particle size diameter range with a D | 08-25-2011 |